Optimizing diagnostic approach to drug-induced liver injury

Maria Giovanna Minissale,1 Maurizio Soresi,1 Massimo Galia,2 Francesco Agnello,2 Lydia Giannitrapani,1 Massimo Midiri,2 Anna Licata1

1Internal Medicine and Hepatology Unit, Biomedical Department of Internal Medicine and Specialties; and 2Section of Radiological Sciences, Di.Bi.Med., P. Giaccone University Hospital, University of Palermo, Italy

ABSTRACT

Drug-induced liver injury (DILI) is often a trial even to expert clinicians, because sometimes diagnosis is not easy to be made. Guidelines of the American College of Gastroenterology (ACG) yielded in 2014, help to better understand the problem. The diagnosis of DILI is made through a detailed evaluation of clinical, serological, radiological and histological aspects. Biochemical data include liver function tests that allow to assess the pattern of damage, such as hepatocellular, cholestatic and mixed liver injury; serological data include testing for major and possibly minor hepatotropic viruses, non-organ specific autoantibodies. Clinical scenario might include jaundice, nausea, vomiting and extra-hepatic manifestations such as fever, pruritus, rash and cosinophilia. Investigation of the potential culprit drugs should involve firstly the temporal relationship between intake of the medication and onset of symptoms, thus the improvement after drug withdrawal. Overall, to complete the diagnostic evaluation, an abdominal ultrasound can be performed, as well as measurement of liver stiffness by transient elastography, and finally liver biopsy, which still represents the most accurate method to definitely assess liver damage. Sometimes, in such cases, computed tomography scan and magnetic resonance could help in the diagnosis of cases presenting with focal lesions of the liver, with cholestatic-like disease or vascular alterations, such as veno-occlusive disease. DILI diagnostic criteria help clinicians thinking of liver injury induced by drug, excluding other causes of liver disease. According to severity of liver damage and type of drug, it is possible to carefully predict the patient’s outcome.

Burden of drug-induced liver injury

Drug-induced liver injury (DILI) is an uncommon condition, which sometimes is responsible for acute liver failure (ALF) and consequently urgent liver transplant.1 Incidence of DILI was between 1 in 10,000 and 1 in 100,000 according to previously published data, however, more recent studies reported that incidence appears higher.1 Recently, the American College of Gastroenterology (AGA) yielded guidelines on Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury,2 providing indications regarding clinical presentation, diagnosis and management. European Countries still did not formulate appropriate rules, but there are several registries both in Western3-7 and in Asian8 countries, which have provided useful information as regards the etiology, pathogenesis as well as the clinical presentation, diagnosis and management of DILI. Further, another help comes from a really useful website, The Liver Tox (available at http://livertox.nlm.nih.gov), which provides information on documented hepatotoxicity of certain drugs, herbal remedies and dietary supplements (HSD). In Europe many projects are ongoing with the final proposal of formulating appropriate guidelines to help clinicians in the management of this still debated issue. For this proposal, the Pro Euro DILI Registry has been created and is actually working on recruiting DILI cases.
Definition of drug-induced liver injury cases

The drug-induced liver injury is defined as liver damage caused by drugs, dietary supplements and herbal products, at usual dose.1 We can distinguish two different types of DILI: intrinsic DILI, with a predictable and dose dependent action (e.g. paracetamol, methotrexate, chemotherapeutic agents); idiosyncratic DILI, unpredictable and not dose dependent. It is less frequent, in susceptible subjects, with variable latency, presentation and course.2,9

Predisposition to idiosyncratic DILI is linked to different variables: associated with the patient (age, gender, race, comorbidity, genetic susceptibility, previous episodes of DILI), associated with environment (alcohol, tobacco, diet, obesity), associated with drug (dosage, chemical structure, administration rout, interaction with other drugs).2,9 Female patients have a greater risk of developing an adverse reaction, because of a slower metabolizing capacity and hormonal interference.10 Potentially all drugs can be involved, but liver damage is commonly caused by antibiotics, non-steroidal anti-inflammatory drugs, statins, anti-platelets, immunosuppressant and HSD.1,11-14

DILI definition criteria changed in the last thirty years. Initially, through the Council of International Organization of Medical Scientists (CIOMS), DILI was defined as an increase of aminotransferases (ALT/AST), alkaline phosphatase (AP), and bilirubin of at least 2 times normal value. After this, RUCAM (NCI) and the World Health Organization (WHO) have developed standardized criteria to quantify the severity of treatment-related abnormalities in liver function tests of patients undergoing chemotherapy.10,20

Predictable drug-induced liver injury cases

Intrinsic or predictable cases of DILI are dose dependent, being due to an overdose of assuming drug. Thus, intrinsic DILI can be usually due to paracetamol, chemotherapeutic agents or methotrexate.

DILI due to paracetamol (acetaminophen, APAP) happens, whenever this drug is taken in excessive doses, for example with suicidal purpose. It can cause acute hepatitis or acute liver failure with a need for urgent liver transplant. Paracetamol causes lobular central necrosis, which manifests with high blood levels of aminotransferases. N-acetyl-cysteine used as antidote, 8 to 24 h after ingestion of high amounts of paracetamol (200 mg/kg or 10 g are toxic dose), can reduce the oxidative effect of free radicals, which are basic to liver damage. Despite the initial severity of acute hepatitis, prognosis is favorable, related to the rapid regeneration of hepatocytes.9,18

The metabolism of altered chemotherapeutic agents can result in systemic toxicity with high or persistent raised drug blood levels. Sometimes, the adverse reaction to chemotherapeutic agents manifests with hepatocellular injury, inflammation and cholestasis, or causes endothelial damage and thrombosis leading to vascular complications such as veno-occlusive disease, also called hepatic sinusoidal obstruction syndrome (SOS). SOS frequently occurs in patients undergoing hematopoietic cell transplantation or receiving combination of fluorouracil with oxaliplatin/irinotecan as neoadjuvant therapy. The National Cancer Institute (NCI) and the World Health Organization (WHO) have developed standardized criteria to quantify the severity of treatment-related abnormalities in liver function tests of patients undergoing chemotherapy.10,20

Herbal and dietary supplements

HDS are commonly responsible for herb-induced liver injury (HILI), because they are not real drugs, so they do not follow the pre-marketing phases of clinical trials, designed to evaluate efficacy and safety of drugs. Further, being a mixture of substances (such as seeds, leaves and roots) herbal drugs can also increase the risk of toxicity.11 Clinical manifestations
can be acute, as fulminant hepatitis and acute liver failure, or chronic, as cholestatic hepatitis, veno-occlusive forms and cirrhosis. People using these products are generally highly educated women, which prefer the use of these products believing they are natural, thus safe. For these reasons, pregnant women, children and elder people, use HDS as well. However, different substances may interact with other drugs, as commonly happens in the elderly, when people are on polytherapy (assuming more than 10-12 tablets a day), thus adding an herbal product can be very hazardous. It is noteworthy that HDS are usually purchased rapidly through the Internet, without any medical prescription, and are frequently used as slimming aids or muscle building. In a certain percentage of the cases, hormonal products used as body building can cause jaundice with a favorable prognosis as compared to other substances (like green tea extracts) which instead determines an unfavorable outcome finally leading to liver transplantation.

**Diagnosis of drug-induced liver injury**

It is made through a detailed clinical history, supported by serological markers, clinical imaging and histological features. There is a lack of consensus on which laboratory threshold criteria should be used to confidently identify DILI cases. In fact, DILI cannot be merely defined by the rise in serum aminotransferases, it requires causality assessment as well. Basically, it remains a diagnosis of exclusion (Figure 1).

In this review, we aim to describe the multistep process for making a diagnosis of DILI/HILI after that clinical, serological and histological assessments have been performed. Thus, radiological data stemmed by abdominal ultrasound (US), transient elastography (TE), computed tomography (CT) scan and magnetic resonance imaging (MRI) of the liver, will further help clinician to confirm or exclude the clinical scenario of DILI.

**Clinical and serological evaluation**

Clinicians should carefully evaluate medications history of patients. Firstly, they should collect demographical data about age, sex, race, morbidity, use of alcohol or other drugs. Secondly, the investigation of a possible drug involved, as first or second exposition, time of drug exposure, temporal relationship between intake and onset of symptoms and possible improvement after drug discontinuation. More and more frequently, the culprit drug has been substituted by HDS. In fact, they are usually marketed without prescription and patients do not disclose to physician their use. DILI manifestations can be evident even months after the start of involved drug, the time to onset of DILI after drug administration varying widely, from few days to even more than one year, making it difficult to adequately find the implicated drug, especially in patients assuming multiple drugs.

Clinical course is changing from asymptomatic disease (diagnosis made occasionally, as a result of examinations routinely performed) to acute clinical presentation with jaundice, dark urine, malaise, anorexia, nausea, skin rash and in the most severe cases signs of hepatic encephalopathy. Extra-hepatic manifestations such as pruritus, rash, fever and eosinophilia in case of hypersensitivity could be investigated, as well. Biochemical assessment of the patient with DILI include liver function tests (LFTs) such as AST/ALT and AP, allowing to define the type of pattern of liver injury. Albumin level decreasing with an increase in total bilirubin and international normalized ratio are usually associated with severe liver dysfunction. When total bilirubin and ALP are persistently elevated, as 30-60 days after the diagnosis, a chronic outcome can be possible. A complete blood count is performed to evaluate eosinophilia, typical in case of hypersensitivity syndrome in DILI.

The first condition to be excluded is acute viral hepatitis, thus through anti-HAV, anti-HCV, HBsAg, anti-HBc major hepatotropic viruses should be rule out; when negative, even minor hepatotropic viruses (cytomegalovirus, Epstein-Barr virus, Herpes simplex virus) should be serologically tested.

Then serum IgG and non-organ specific autoantibodies (ANA, AMA, ASMA, LKM) are useful to exclude autoimmune liver damage. It is noteworthy, that in some cases, a slightly positivity for ANA (1:80 or 1:160) with a speckled pattern can be present. This finding does not mean that the patient is suffering from an autoimmune hepatitis needing corticosteroids or immunosuppressant therapy. In such cases, drugs can unmask an underlying autoimmune disease, but the diagnosis is histological. AMA and p-ANCA can be investigated when there is a cholestatic pattern, to completely exclude primary biliary cholangitis or primary sclerosing cholangitis (Figure 1).

Alfa-1 antitrypsin, ceruloplasmin, and iron markers are evaluated to exclude genetic disease as cystic fibrosis, Wilson disease and hemochromatosis, and all of them can be evaluated at a later time, also because of the usual character of chronicity of these diseases.

**Emerging biomarkers**

Transaminases, ALT and AST, AP and total bilirubin are currently the only DILI biomarkers approved in clinical practice. Although playing an important role in the diagnosis of all liver diseases, they are not specific for hepatotoxicity, as the increase
in these values is common in all pathological liver conditions. The usefulness of having biomarkers with high specificity and sensitivity would allow identifying earlier potentially hepatotoxic drugs in the drug development process and subsequently to reduce the number of post-marketing drugs withdrawn. However, these biomarkers could be useful in assessing DILI, not really available in clinical practice. Further, the ability to validate new DILI biomarker candidates is restricted due to the current lack of fully functional animal models for idiosyncratic DILI. The Pro-Euro-DILI Registry is collecting serial biological samples from DILI onset to normalization of enrolled patients, for future DILI biomarker studies and validations.²⁵,²⁶

Among the DILI candidate new biomarkers, there are the mechanistic-based biomarkers such as glutamate dehydrogenase (GLDH), the high mobility group box 1 protein (HMGB1) and keratin-18 (K18), which can also provide information on the mechanism of necrosis of the different causal agents.

GLDH is a mitochondrial enzyme that is found mainly in the liver as compared with kidneys and muscles. An increase in the level of circulating GLDH indicates mitochondrial dysfunction, which usually occurs during hepatocellular necrosis. GLDH correlates well with the increase of ALT in patients with various forms of liver injury, including overdose of APAP, although GLDH does not precede ALT elevation resulting from APAP hepatotoxicity. HMGB1 is a chromatin-binding protein with pro-inflammatory activity;²⁷ K18, full length and caspase cleaved-K18, indicates the degree of cellular necrosis and apoptosis that occurs in the subject. It has also been found that these biomarkers are more sensitive than ALT, with early increases compared to ALT in patients at the first presentation after APAP overdose.²⁸

MicroRNAs (miRNAs) are small non-coding RNAs (20-24 nucleotides) involved in post-transcriptional regulation of gene expression. Recently they received a lot of attention as potential non-invasive DILI biomarkers candidates.²⁹ MiR-122 and

---

Figure 1. Algorithm to diagnose drug-induced liver injury. HDS, herbal and dietary supplements; CBC, complete blood count; ALT, alanine aminotransferase; AP, alkaline phosphatase; INR, international normalized ratio; Anti HAV, hepatitis A virus antibodies; Anti HCV, hepatitis C virus antibodies; HBs Ag, hepatitis B surface antigen; Anti HBe, hepatitis B core antibodies; ANA, antinuclear antibodies; AMA, antimitochondrial antibodies; ASMA, antismooth muscle antibodies; p-ANCA, anti-neutrophil cytoplasmic antibodies; LKM, antismicrosomal liver kidney antibodies; DILI, drug-induced liver injury; HILI, herbal-induced liver injury; CT-scan, computed tomographic scan; NMR, nuclear magnetic resonance.
miR-192 were the first circulating miRNAs that were shown to increase after doses of toxic APAP in mice and soon thereafter confirmed that they behaved similarly in humans, even before hepatocellular damage occurred. Emerging data also indicate that miRNA-122 may have a prognostic value, with higher early serum levels reported in patients with APAP overdose who met the King’s College criteria for liver transplantation.

Th1 [interleukin (IL)12, interferon γ, IL2, IL15] and Th2 (IL4, IL5, IL13) cytokines are usually activated by an acute stimulus. If inflammation does not resolve, it can evolve into a chronic response of immunological system (Th17/Th19) with a severe prognosis.

Biomarkers derived from Omics, as metabolomics and proteomics, are a large number of molecules (metabolites, proteins, DNA) that allow the identification of the toxicity signature; these could be used to improve preclinical safety assessment and DILI disease diagnostics. An exploratory comparison of global serum proteomes in DILI has reported promising results with apolipoprotein E expression demonstrating the greater power to differentiate DILI from controls (Table 1). Unfortunately, these biomarkers are not yet available in clinical practice, but only experimentally.

Histological pattern

Even if liver biopsy is often not required, it still represents the golden standard to assess liver damage by drugs, confirming a doubtful clinical suspicion and ruling out underlying chronic liver disease (viral, alcoholic, metabolic). Characteristics of a liver biopsy in DILI are fibrosis, steatosis, necro-inflammation, granulomas, lipofuscin, cholestasis. DILI could be associated with autoimmune hepatitis (DIAIH), which occurs mainly in women, with positivity of auto-antibodies, high levels of transaminases and gamma-globulin, features of liver histology such interface hepatitis, lymphoplasmacytic infiltrate, rosettes and cholestasis, and with a better prognosis as compared with autoimmune hepatitis properly defined. Recent data, suggest an association with certain HLA gene variants, with alteration of specific cytokines and inhibition of some hepatobiliary transporters. Drug-Induced Liver Injury Network (DILIN) prospective study showed that most cases of DILI attributed to nitrofurantoin or minocycline and about half of cases due to methyldopa and hydralazine had a phenotype of autoimmunity similar to AIH. These features decrease with recovery of the injury and are not associated with the typical HLA alleles found in patients with idiopathic AIH. The clinical characteristics of DILI, which showed histological findings similar to AIH, were revealed. In such patients, a liver biopsy is recommended in order to determine the appropriate treatment strategy. In DILI with histology-like AIH patients, long-term follow-up is needed to perceive the relapse. LFT results positively correlated with

| Table 1. Useful biomarkers in clinical practice associated with drug-induced liver injury. |
|----------------------------------------|----------------------------------------|
| **Biomarker**                          | **Drug-induced liver injury**          |
| ALT, AST, AP, Bilirubin                | Acute and chronic                     |
| Sorbitol dehydrogenase                | Acute                                 |
| Glutathione S-transferase             | Liver and kidney                      |
| Serum cytokine profiles               | Acute and chronic                     |
| Th1                                   |                                        |
| Th2                                   |                                        |
| Th17/Th19                             |                                        |
| miRNAs                                | Acute and chronic                     |
| miR-122                               | APAP overdose                         |
| miR-192                               |                                        |
| Glutamate dehydrogenase               | Marker of necrosis                    |
| HMGB-1                                | Marker of necrosis                    |
| K18 (full-length and ccK18)           | Marker of apoptosis                   |
| Apolipoprotein E                      | Acute                                 |

ALT, alanine aminotransferase; AST, aspartate aminotransferase; AP, alkaline phosphatase; Th1, Th2, Th17/Th19, T helper lymphocytes; miRNAs, micro RNA; APAP, acetaminophen; HMGB-1, high mobility group box-1 protein; K18, keratin 18. Modified from Licata, 2016.
histological findings. DILI can manifest as predominantly hepatitis, bile duct injury or combination. Histological pattern recognition in the liver biopsy may help to identify specific hepatotoxic agents causing DILI. Liver biopsies from subjects with DILI were characterized by low counts of mature B cells and natural killers (NK) cells in portal tracts in contrast with viral hepatitis. NK cells were found only in viral cases, whereas both (AIH and viral hepatitis) showed higher counts of B cells than DILI. Plasma cells were most strongly associated with AIH. Chemotherapy-induced liver injury involves oxidative stress with pathological findings such as sinusoidal dilatation, peliosis, perisinusoidal fibrosis, regenerative nodular hyperplasia. In other cases, there are deposition of lipid vesicles, lobular inflammation causing steatosis and steatohepatitis. These conditions can mimic liver metastasis, as well.

**Radiological assessment**

**Abdominal ultrasound**

The abdominal US in the DILI is one of the first diagnostic tools that has been performed, because, in the presence of liver disease, this method, inexpensive, non-invasive, readily available and acceptable to patients, gives a series of very useful information. However, US in DILI does not show specific signs but it is mainly used to exclude other liver diseases and to address diagnosis. For example, in cholestatic liver damage, US will exclude obstructive jaundice because it will not detect dilated bile ducts and will make us thinking of a medical rather than surgical cholestasis. One of the most frequent signs in DILI, is the steatosis, seen at ultrasound as the bright liver echo pattern which could be determined by various drugs. This echo pattern shows markedly increased the liver/kidney contrast, defined as the relative brightness of the liver to the renal parenchyma when compared in longitudinal scanning involving both these organs (Figure 2). However, steatosis is common in obese patients and ultrasound did not show specific signs allowing us to differentiate between steatosis by drugs or steatosis by steatohepatitis, so even in this case liver US relieves only a small piece in the complex mosaic that usually is the diagnosis of DILI.

Sinusoidal obstruction syndrome (SOS), previously named veno-occlusive disease, is a disease resulting from the use of chemotherapeutic drugs and it affects prevalently patients undergoing regimes in the setting of haematopoietic stem cell transplantation. There are no typical ultrasound signs but in the clinical context the evidence of one of them must make SOS suspect. The most frequent signs are: signs of portal hypertension showed by Doppler ultrasound, liver and spleen enlargement, recanalization of para-umbilical

![Figure 2. The bright liver. The relative brightness of the liver to the renal parenchyma when compared in longitudinal scanning involving both these organs.](image-url)
vein, ascites, gallbladder wall thickening, and portal vein thrombosis. Doppler evaluation of portal flow shows either maximal velocity <10 cm/s, biphasic flow, or complete flow reversal in severe cases (Figure 3).49,50

Portal vein thrombosis is a rare complication of DILI and ultrasound identifies echoes inside the vessel (thrombi) obstructing partially or completely.51

In chronic DILI ultrasound can also show irregular surfaces of the liver, variable echo patterns, signs of portal hypertension and spleen enlargement, as in all chronic liver diseases.

**Transient elastography**

New diagnostic tools have been developed which, when supported by ultrasound, permit the estimation of fibrosis.51-53

Transient elastography is a useful non-invasive technique for monitoring liver fibrosis in patient taking methotrexate (MTX)54 because suffering from psoriasis, with abnormal results (7-11 Kpa). Presence of overweight or obesity, duration of MTX therapy and cumulative dose were correlated with abnormally elevated TE results.55 It is also a good tool for evaluating hepatic injury after FOLFOX treatment.56

In fact, a clear change in liver stiffness was observed after chemotherapy within 48 h, and it became normal in most of cases after 2 weeks. Some patients can show aberrant elevation of TE values after a FOLFOX treatment, showing pathologically liver injury.56

Liver stiffness increase, in association with raised liver enzymes, have been linked to acute inflammation or acute intrahepatic cholestasis.57 TE could be used to differentiate acute and acute on chronic liver failure (ACLF), in fact patients with acute liver damage have significantly lower fibrosis (thus lower liver stiffness estimation) than patients with ACLF.58

The hepatic toxicity showed by altered hepatic biochemical tests and by symptoms of liver disease needs information obtained through liver biopsy or by assessing the hepatic elasticity or stiffness through elastography. Thus, elastography is useful in assessing the chemotherapy related hepatotoxicity with cancer, also in children.59

**Computed tomography and magnetic resonance imaging**

With the increasing use of CT and MRI, most DILI can be initially suspected at imaging instead of clinical examination. Imaging findings, however, are often non-specific and a clinical-biochemical correlation is required to achieve the correct diagnosis.

A severe and life-threatening DILI is acute hepatitis. CT and MRI findings are non-specific, and include hepatomegaly with decreased parenchymal enhancement, periportal edema, gallbladder wall thickening and ascites (Figure 4).60 Hepatic SOS is the result of blockage of small hepatic veins with consequent hepatic venous stasis. CT and MRI cannot directly demonstrate vascular damage, but certain imaging findings due to hepatic venous stasis can

Figure 3. Patient with sinusoidal obstruction syndrome, complete flow reversal in portal vein.
suggest a correct diagnosis in an appropriate clinical setting. These include hepatomegaly with patchy parenchymal enhancement, perportal edema, gallbladder wall thickening and narrowing of main hepatic veins. MR can also show multiple hyperintense areas on T2-weighted images, and reticular hypointensity of the liver on hepatobiliary phase with Gd-EOB-DTPA. \(^{61,62}\) Signs of portal hypertension such as splenomegaly, esophageal varices and ascites can also be seen, and indicate a more advanced stage of SOS. \(^{62}\) SOS can also manifest as a focal lesion, and radiologically mimic a metastasis. Non-spherical shape, ill-defined margin, intermingled hypo- or hyperintensity on hepatobiliary phase MR images, and isointensity on high-b-value diffusion-weighted MR images favor a diagnosis of metastasis over focal SOS.

Drug-induced sclerosing cholangitis is usually difficult to diagnose at imaging. CT and MR can show a similar appearance to primary sclerosing cholangitis, with narrowing of bile ducts. \(^{63,64}\) Magnetic resonance cholangiopancreatography helps differentiate these two entities by demonstrating primary involvement of bile ducts at the hepatic portal in drug-induced sclerosing cholangitis. \(^{63}\) Contrast-enhanced CT or MRI can also show periductal edema, enhanced and thickened bile duct wall, and heterogeneous liver enhancement. \(^{64}\)

Conclusions

In this review we wanted to underline that, DILI, although epidemiologically affecting a lower percentage of cases compared to other liver diseases, sometimes can be severe as life threatening unless a transplant is performed. Despite the numerous and increasing evidence in the literature concerning the attempt to identify damage patterns related to a specific drug, as well as biomarkers useful not only in diagnosing but also in predicting the outcome, even today the diagnosis of DILI is still a diagnosis of exclusion. An ever-increasing support comes from both radiological and ultrasonographic imaging techniques. In fact, they do not allow to make the diagnosis, but to exclude other pathologies, whose resolution is not spontaneous, and to show clinical pictures (steatosis or VOS), which are typical of patients with DILI. CT and MRI are second level techniques of imaging and should be used for a differential diagnosis (to exclude gallstones, pancreatic disease, sclerosing cholangitis) or when we want to provide particular information of some aspect of DILI (e.g. SOS). The presence of networks dedicated to this pathology both in the USA (DILIN Network) and in Europe (ProEuroDili Network) will surely allow in the near future knowing with greater certainty the pathogenic mechanisms that underlie DILI and therefore the possibility to predict it.

References

1. Bjornsson ES. Drug-induced liver injury: an overview over the most critical compound. ArchToxicol 2015;89:327-34.
2. Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol 2014;109:950-6.
3. Hoofnagle JH. Drug induced liver injury. Network (Dilin) Hepatol 2004;40:773.
4. Sgro C, Clinard F, Ouazir K, et al. Incidence of drugs induced hepatic injuries: a French population-based study. Hepatology 2002;35:451-5.
5. Andrade RJ, Lucena MI, Fernandez MC, et al. Drug-
induced liver injury: an analysis of 461 incidences submitted to Spanish registry over a 10 year period. Gastroenterology 2005;129:512-21.
6. Bjornsson ES, Bergmann OM, Kvaran RB, et al. Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 2013;144:1419-25.
7. Licata A, Minissale MG, Calvaruso V, Craxi A. A focus on epidemiology of drug induced liver injury: analysis of a prospective cohort. Eur Rev Med Pharmacol Sci 2017;21:112-21.
8. Takikawa H, Murata Y, Horiike N, et al. Drug-induced liver injury in Japan: an analysis of 1676 cases between 1997 and 2006. Hepatol Res 2009;39:427-31.
9. Licata A. Adverse drugs reactions and organ damage: the liver. EJIM 2016;28:9-16.
10. Para O, Crispino P, Barone N, et al. Sex differences in adverse drug reaction and liver disease. Ital J Med 2018;12:1522.
11. Licata A, Macaluso FS, Craxi A. Herbal hepatotoxicity: a hidden epidemic Intern Emerg Med 2013;8:13-22.
12. Licata A, Puccia F, Lombardo V, et al. Rivaroxaban induced hepatotoxicity: review of the literature and report of new cases. Eur J Gastroenterol Hepatol 2018;30:226-32.
13. Licata A, Calvaruso V, Cappello M, et al. Clinical course and outcomes of drug-induced liver injury: Nimesulide as the first implicated medication. Dig Liv Dis 2010;42:143-8.
14. Licata A, Randazzo C, Morraele I, et al. Fluoroquinolone-induced liver injury: three new cases and a review of the literature. Eur J Clin Pharmacol 2012;68:525-32.
15. Danan G, Benichou C. Causality assessment of adverse reaction to drugs - A novel method based on the conclusions of international consensus meeting: application to drug-induced liver injuries. J Clin Epidemiol 1993;46:1323-30.
16. Benichou Danan G, Flahaut A. Causality assessment of adverse reactions to drugs. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 1993;43:1331-6.
17. Maria VA, Victorino RM. Development and validation of a clinical scale for the diagnosis of drug induced hepatitis. Hepatology 1997;26:664-9.
18. Heard K, Rumack BH, Green JL, et al. A single-arm clinical trial of a 48-hour i.v. N-acetylcysteine protocol for treatment of acetaminophen poisoning. Clin Toxicol 2014;52:1-8.
19. Houghton AN, Shafi N, Rickles FR. Acute hepatic vein thrombosis occurring during therapy for Hodgkin's disease: a case report. Cancer 1979;44:23-4.
20. Floyd J, Mirza I, Sachs B, Perry MC. Hepatotoxicity of chemotherapy. Semin Oncol 2006;33:50-67.
21. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med 2006;354:731-9.
22. Reich CG, Ryan PB, Schemie M. Alternative outcome definitions and their effect on the performance of methods for observational outcome studies. Drug Saf 2013;36:181-93.
23. Lindor KD, Gershwin ME, Poupon R, et al. Primary biliary cirrhosis. Hepatology 2009;50:291-308.
24. Noroski LM, Fuleihan R. Primary sclerosing cholangitis. N Engl J Med 2016;375:2501.
25. Robles Diaz M. Biomarker in DILI: one more step forward. Front Pharmacol 2016;22:267.
26. Schomaker S, Warner R, Bock C, et al. Assessment of emerging biomarkers of liver injury in human subjects. Toxicol Sci 2013;132:276-83.
27. Kubis P, Mehal WZ. Sterile inflammation in the liver. Gastroenterology 2012;143:1158-72.
28. Antoine DJ, Dear JW, Lewis PS, et al. Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital. Hepatology 2013;58:777-87.
29. Wang K, Zhang S, Marzolf B, et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci U S A 2009;106:4402-7.
30. Starkey Lewis PJ, Dear J, Platt V, et al. Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology 2011;54:1767-76.
31. Steuerwald NM, Foureaux DM, Norton HJ, et al. Profiles of serum cytokines in acute drug-induced liver injury and their prognostic significance. PLoS One 2013;8:19174.
32. Bell N, Vuppalanchi R, Watkins PB, et al. Serum proteomic profiling in patients with drug-induced liver injury. Aliment Pharmacol Ther 2012;35:600-12.
33. Alempijevic T, Zee S, Milosavljevic T. Drug induced liver injury: Do we know everything? World J Hepatol 2017;9:491-502.
34. Licata A, Maida M, Cabibi D, et al. Clinical features and outcomes of patients with drug-induced autoimmune hepatitis: a retrospective cohort study. Dig Liver Dis 2014;46:1116-20.
35. Athal GP, Ramsay L, Daly AK, et al. Hepatic adducts, circulating antibodies, and cytokine polymorphism in patients with diclofenac hepatotoxicity. Hepatology 2004;39:1430-40.
36. Magnus Pauli C, Meier PJ. Hepatobiliary transporters and drugs induced cholestasis. Hepatology 2006;44:778-87.
37. De Boer YS, Kosinski AS, Urban TJ, et al. Drug-induced liver injury networkfeatures of autoimmune hepatitis in patients with drug-induced liver injury. Clin Gastroenterol Hepatol 2017;15:103-12.
38. Hisamochi A, Kage M, Ide T, et al. An analysis of drug-induced liver injury, which showed histological findings similar to autoimmune hepatitis. J Gastroenterol 2016;51:597-607.
39. Ettel M, Gonzalez GA, Gera S, et al. Frequency and pathological characteristics of drug-induced liver injury in a tertiary medical center. Hum Pathol 2011;42:92-8.
40. Foureaux DM, Walling TL, Maddukuri V, et al. Comparative analysis of portal hepatic infiltrating leucocytes in acute drug-induced liver injury, idiopathic autoimmune and viral hepatitis. Clin Exp Immunol 2015;180:40-51.
41. You SH, Park BJ, Kim YH. Hepatic lesions that mimic autoimmune and viral hepatitis. Clin Exp Immunol 2004;39:1430-40.
42. Cleary JM, Tanabe KT, Lauwers GY, et al. Hepatic metastasis on radiological imaging during chemotherapy. J Radiol 2017;180:40-51.
43. Li Vecchi V, Giannitrapani L, Di Carlo P, et al. Non-invasive assessment of liver steatosis and fibrosis in HIV/HCV- and HCV-infected patients. Ann Hepatol 2013;12:740-8.

44. Soresi M, Giannitrapani L, Florena AM, et al. Reliability of the bright liver echo pattern in diagnosing steatosis in patients with cryptogenic and HCV-related hypertransaminasemia. Clin Radiol 2009;64:1181-7.

45. Hernaez R, Lazo M, Bonekamp S, et al. Diagnostic accuracy and reliability of ultrasoundography for the detection of fatty liver: a meta-analysis. Hepatology 2011;54:1082-90.

46. Soresi M, Giannitrapani L, Noto D, et al. Effects of steatosis on hepatic hemodynamics in patients with metabolic syndrome. Ultrasound Med Biol 2015;41:1545-52.

47. Soresi M, Noto D, Cefalu AB, et al. Nonalcoholic fatty liver and metabolic syndrome in Italy: results from a multicentric study of the Italian Arteriosclerosis society. Acta Diabetol 2013;50:241-9.

48. Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002;123:745-50.

49. European Association for the Study of the Liver. EASL clinical practice guidelines: vascular diseases of the liver. J Hepatol 2016;64:179-202.

50. Alessandrino F, Tirumani SH, Krajewski KM, et al. Imaging of hepatic toxicity of systemic therapy in a tertiary cancer centre: chemotherapy, haematopoietic stem cell transplantation, molecular targeted therapies, and immune checkpoint inhibitors. Clin Radiol 2017;72:521-33.

51. Soresi M, Giannitrapani L, Cervello M, et al. Non invasive tools for the diagnosis of liver cirrhosis. World J Gastroenterol 2014;20:18131-50.

52. European Association for Study of Liver; Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH clinical practice guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 2015;63:237-64.

53. Dietrich CF, Bamber J, Berzigotti A, et al. EFSUMB guidelines and recommendations on the clinical use of liver ultrasound elastography, update 2017 (long version). Ultraschall Med 2017;38:16-47.

54. Barbero-Villares A, Mendoza J, Trapero-Marugan M, et al. Evaluation of liver fibrosis by transient elastography in methotrexate treated patients. Med Clin 2011;137:637-9.

55. Lynch M, Higgins E, McCormick PA, et al. The use of transient elastography and Fibrotest for monitoring hepatotoxicity in patients receiving methotrexate for psoriasis. JAMA Dermatol 2014;150:856-62.

56. Oki E, Kakeji Y, Taketomi A, et al. Transient elastography for the prediction of oxaliplatin-associated liver injury in colon cancer patients: a preliminary analysis. J Gastrointest Cancer 2008;39:82-5.

57. Kakisaka K, Kooka Y, Oikawa T, et al. Bimodal peaks of liver stiffness in a case of drug induced liver injury. Hepatol 2015;45:343-8.

58. Sharma P, Bansal R, Matin A, et al. Role of transient elastography (Fibroscan) in differentiating severe acute hepatitis and acute on chronic liver failure. J Clin Exp Hepatol 2015;5:303-9.

59. Marginean CO, Baghiu MD, Branzaniuc K, et al. The role of real-time elastography in the evaluation of post chemotherapy hepatotoxicity in children with cancer. Rev Med Chir Soc Med Nat Iasi 2011;115:70-7.

60. Sharma A, Houshyar R, Bhosale P, et al. Chemotherapy induced liver abnormalities: an imaging perspective. Clin Mol Hepatol 2014;20:317-26.

61. Shin NY, Kim MJ, Lim JS, et al. Accuracy of gadoxetic acid-enhanced magnetic resonance imaging for the diagnosis of sinusoidal obstruction syndrome in patients with chemotherapy-treated colorectal liver metastases. Eur Radiol 2012;22:864-71.

62. McGettigan MJ, Menias CO, Gao ZJ, et al. Imaging of drug-induced complications in the gastrointestinal system. Radiographics 2016;36:71-87.

63. Sandrasegaran K, Alazmi WM, Tann M, et al. Chemotherapy-induced sclerosing cholangitis. Clin Radiol 2006;61:670-8.

64. Phongkitkarun S, Kobayashi S, Varavithya V, et al. Bile duct complications of hepatic arterial infusion chemotherapy evaluated by helical CT. Clin Radiol 2005;60:700-9.